Compare MasTec Inc (MTZ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Twist Bioscience Corp — how do they compare? MasTec Inc trades at $218.21 (market cap $17.40B), while Twist Bioscience Corp trades at $159.69 (market cap $10.08B). The key difference: MasTec Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Twist Bioscience Corp for 27 Days on average.
| MTZ | TWST | |
|---|---|---|
Market Cap | $17.40B | $10.08B |
Volume | 1,415,821 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $437.51 | $205.00 |
52-Week Low | $190.08 | $25.45 |
Typical Hold Time | 23 Days | 27 Days |
Enterprise Value | $20.32B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $223.37, down 2.16% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamentals with Q1 2026 earnings beating expectations and a robust 88.9% analyst buy rating. Recent news highlights MTZ's positioning to benefit from infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4 billion backlog.
The outlook remains positive given strong institutional support and infrastructure tailwinds, though premium valuation and communications segment softness pose risks. With a consensus price target of $408.58 representing 83% upside potential, the stock offers significant growth opportunity for investors comfortable with execution risks in the competitive infrastructure sector.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
